CDH Investments (VGC) Research
Investment Thesis
CDH Investments is a major Beijing-headquartered alternative asset manager founded in 2002, with over $20 billion in assets under management across Private Equity, Venture & Growth Capital, Private Credit, Public Equities, and Real Assets. Its venture arm, CDH VGC (Venture and Growth Capital), was founded in 2015 with the stated mission of "investing in technological innovation to drive value creation with social impact." VGC's own framing is that its name is the organic combination of Venture and Growth Capital: it examines a project's growth potential from a VC lens (fit with industry trends) while also applying a growth investor's discipline (risk control, execution quality) to pursue high-quality investments with excess returns.
Sector Focus
Through in-depth, forward-looking industry research, VGC sources opportunities in four core areas: healthcare, artificial intelligence & technology, consumer, and enterprise solutions. In practice, the portfolio skews heavily toward hard technology: embodied AI and robotics (AGIBOT, Lumos Robotics), autonomous driving (Momenta), semiconductors (Loongson, Yeestor, Allystar, Vimicro, PIP Semiconductor), biomanufacturing and biotech (Harbour Biomed, I-Mab Biopharma, Virogin Biotech, GemPharmatech, Singleron, Hitgen), and aerospace/space (I-space, Tianlian Aerospace, Mino Space). CDH's broader platform (300+ portfolio companies across all business lines) also includes large consumer and industrial names, but those largely sit with CDH's flagship PE funds rather than VGC.
Stage Focus
VGC invests across venture and growth stages, from early Series A into growth rounds, generally as a repeat/continuation investor in existing portfolio companies through later rounds (e.g., continuing into Kangweijian Bio's Series B after an earlier check). Exact check-size bands are not publicly disclosed; Reuters reported VGC's first fund alone deployed more than $600M across its portfolio.
Lead Tendency
Mixed: VGC has led rounds outright (Lumos Robotics' combined Pre-A1/Pre-A2), co-led alongside other institutional investors (Zhongshu Ruizhi's Series A+ with Beijing AI Fund), and participated as a continuation/non-lead investor in later rounds of existing portfolio companies (Kangweijian Bio Series B).
Recent Activity
VGC remains actively deploying into AI, robotics, and biotech in 2025-2026. Recent disclosed activity includes co-leading a RMB 200M Series A+ round for AI company Zhongshu Ruizhi (July 2025), continuing into Kangweijian Bio's Series B (September 2025), and leading Lumos Robotics' combined Pre-A financing (reported within the last year). On the exit side, portfolio company Momenta (autonomous driving) completed a $751M Hong Kong IPO on July 8, 2026, valuing the company at roughly $9 billion; fellow robotics portfolio company AGIBOT was reported in July 2026 to be eyeing its own Hong Kong listing at a valuation near $15.6 billion.
Portfolio Highlights
Notable current and past portfolio companies span embodied AI/robotics (AGIBOT, Momenta, Lumos Robotics, Zensmart, Even Realities, Neolix, Ada Intelligent Equipment), semiconductors (Loongson, Yeestor, Allystar, Vimicro, PIP Semiconductor, Tianyi Hexin), biotech/biomanufacturing (Harbour Biomed, I-Mab Biopharma, Virogin Biotech, GemPharmatech, Singleron, Hitgen, Genfleet, AusperBio, ZYLOX-TONBRIDGE, Kanghong, Changmugu/LongWood Valley, COMVIKIN, EVOPOINT), and aerospace (I-space, Tianlian Aerospace, Mino Space). Exits/liquidity events include GemPharmatech's 2022 STAR Market listing, Momenta's 2026 Hong Kong IPO, and Well-link, which won AVCJ's "Deal of the Year – Small Cap 2022" after a B2 round backed by Temasek, CDH VGC, and Future Capital.
Team
- Wang Lin, Head of VGC / Managing Partner — Co-founding partner of CDH (joined 1999 at CICC before co-founding CDH in 2002); 27 years in investing, leads VGC's overall strategy including AI and consumer-AI theses.
- Huang Yan, Managing Partner
- Wang Mingyu, Senior Partner
- Guo Qizhi, Senior Partner
- Gao Jieliang, Senior Partner — Focuses on biomanufacturing and healthcare innovation; recognized on PEdaily's "F40 Influential Investors" list (2022) and "Top 30 Influential Young Investor" (2021).
- Victor Wang, Senior Partner
Decision Process
Institutional partnership structure with a Head of VGC (Wang Lin) plus multiple managing/senior partners covering distinct sector verticals (e.g., Gao Jieliang on biomanufacturing/healthcare) — consistent with a partnership-style decision process rather than a solo-GP model, though the exact investment-committee mechanics are not publicly disclosed.
Founder Preferences
VGC's public materials emphasize backing "scientist entrepreneurs" — the firm cites 40+ scientist entrepreneurs among its founders and highlights deep technical/scientific founding teams in hard tech, biomanufacturing, and AI as a differentiator versus generalist consumer or software investors.
Geographic Focus
Primarily Mainland China (Beijing-headquartered), with CDH's broader platform extending into Hong Kong and Southeast Asia; VGC's disclosed portfolio is overwhelmingly China-based.
Firm-Level Context
At the CDH Investments firm level (encompassing VGC and CDH's other business lines — Private Equity, Private Credit, Public Equities, and Real Assets), the firm has invested in 300+ companies and helped more than 100 list on international and China's domestic exchanges (19 IPOs cited specifically for VGC), with GIC among its founding institutional backers.